Quantitative genomic RNA from Severe acute respiratory syndrome-related coronavirus 2 strain USA/CA_CDC_5574/2020 (variant B.1.1.7)
VR-3326D ™
Download Genome Learn about the ATCC Genome PortalVR-3326D ™
Download Genome Learn about the ATCC Genome PortalATCC determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), U.S. Department of Health and Human Services. It is your responsibility to understand the hazards associated with the material per your organization’s policies and procedures as well as any other applicable regulations as enforced by your local or national agencies.
Genomic RNA isolated from a preparation of Severe acute respiratory syndrome-related coronavirus 2 isolate USA/CA_CDC_5574/2020.
This isolate is lineage B.1.1.7, clade GR according to GISAID (Global Initiative on Sharing All Influenza Data) conventions.
The following mutations were identified in the clinical isolate: Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y145del, M (Membrane protein) V70L, N (Nucleocapsid protein) D3L, N G204R, N R203K, N S235F, NS3 T223I, NS8 (Non-structural protein 8) Q27stop, NS8 R52I, NS8 Y73C, NSP3 (Non-structural protein 3) A890D, NSP3 I1412T, NSP3 T183I, NSP6 (Non-structural protein 6) F108del, NSP6 G107del, NSP6 S106del, NSP12 (Non-structural protein 12) P323L, NSP13 (Non-structural protein 13) A454V, NSP13 K460R.
One additional SNP in ORF1ab L3826F was reported in the deposited passage two virus, in comparison to the clinical specimen.
Genomic RNA from SARS-CoV-2 must be handled at BSL-2 containment.
Innocuity testing was performed on the extracted RNA and results reported on the Certificate of Analysis.
Acknowledgment for publications should read "The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: Genomic RNA from SARS-Related Coronavirus 2, Isolate USA/CA_CDC_5574/2020 (Lineage B.1.1.7), NR-55244."
The product is provided 'AS IS' and the viability of ATCC® products is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product information sheet, website, and Certificate of Analysis. For living cultures, ATCC lists the media formulation and reagents that have been found to be effective for the product. While other unspecified media and reagents may also produce satisfactory results, a change in the ATCC and/or depositor-recommended protocols may affect the recovery, growth, and/or function of the product. If an alternative medium formulation or reagent is used, the ATCC warranty for viability is no longer valid. Except as expressly set forth herein, no other warranties of any kind are provided, express or implied, including, but not limited to, any implied warranties of merchantability, fitness for a particular purpose, manufacture according to cGMP standards, typicality, safety, accuracy, and/or noninfringement.
This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from ATCC.
While ATCC uses reasonable efforts to include accurate and up-to-date information on this product sheet, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate or complete and the customer bears the sole responsibility of confirming the accuracy and completeness of any such information.
This product is sent on the condition that the customer is responsible for and assumes all risk and responsibility in connection with the receipt, handling, storage, disposal, and use of the ATCC product including without limitation taking all appropriate safety and handling precautions to minimize health or environmental risk. As a condition of receiving the material, the customer agrees that any activity undertaken with the ATCC product and any progeny or modifications will be conducted in compliance with all applicable laws, regulations, and guidelines. This product is provided 'AS IS' with no representations or warranties whatsoever except as expressly set forth herein and in no event shall ATCC, its parents, subsidiaries, directors, officers, agents, employees, assigns, successors, and affiliates be liable for indirect, special, incidental, or consequential damages of any kind in connection with or arising out of the customer's use of the product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, ATCC is not liable for damages arising from the misidentification or misrepresentation of such materials.
Please see the material transfer agreement (MTA) for further details regarding the use of this product. The MTA is available at www.atcc.org.
Rambaut A, et al. A Dynamic Nomenclature Proposal for SARS-CoV-2 Lineages to Assist Genomic Epidemiology. Nat Microbiol 5: 1403-1407, 2020. PubMed: 32669681
Mercatelli D and Giorgi FM. Geographic and Genomic Distribution of SARS-CoV-2 Mutations. Front Microbiol: doi.org/10.3389/fmicb.2020.01800, 2020. PubMed: 32793182
Gralinski LE and Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses 12: 135, 2020. PubMed: 31991541
Baczenas JJ, et al. Propagation of SARS-CoV-2 in Calu-3 Cells to Eliminate Mutations in the Furin Cleavage Site of Spike. Viruses 13(12): 2434, 2021.